Year: 2020
Type: article
Abstract: Mitochondrial disorders affect 1/5,000 and have no cure. Inducing mitochondrial biogenesis with bezafibrate improves mitochondrial function in animal models, but there are no comparable human studies. We performed an open-label observational experimental medicine study of six patients with mitochondrial myopathy caused by the m.3243A>G MTTL1 mutation. Our primary aim was to determine the effects of bezafibrate on mitochondrial metabolism, whilst providing preliminary evidence of safety and efficacy using biomarkers. The participants received 600-1,200 mg bezafibrate daily for 12 weeks. There were no clinically significant adverse events, and liver function was not affected. We detected a reduction in the number of complex IV-immunodeficient muscle fibres and improved cardiac function. However, this was accompanied by an increase in serum biomarkers of mitochondrial disease, including fibroblast growth factor 21 (FGF-21), growth and differentiation factor 15 (GDF-15), plus dysregulation of fatty acid and amino acid metabolism. Thus, although potentially beneficial in short term, inducing mitochondrial biogenesis with bezafibrate altered the metabolomic signature of mitochondrial disease, raising concerns about long-term sequelae.
Source: EMBO Molecular Medicine
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,600
Funders: Wellcome Trust, Newton Fund, Alan Turing Institute, UK Research and Innovation, NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, National Institute for Health and Care Research, University of Cambridge, Newcastle University, Cambridge University Hospitals, Newcastle upon Tyne Hospitals NHS Foundation Trust, Evelyn Trust, Lily Foundation, Medical Research Council, Engineering and Physical Sciences Research Council, FP7 Ideas: European Research Council
Awards: Exploring novel molecular targets in mitochondrial protein synthesis to develop treatments in mitochondrial disease., G1309768829, Strengthening the neuromuscular junction as a new concept for the treatment of congenital myasthenic syndromes and motor neuropathies with synaptic dysfunction, G1633672591, G1775096572, G3252469178, G3284490502, New genomic approaches to explore the neurogenetic disease burden of consanguineous marriages in Turkey, G3855435662, G4335143496, The Alan Turing Institute, Nuclear genomic control of mitochondrial DNA heteroplasmy in humans: population genetics & disease, Investigation of the function of the ER/mitochondria contact sites in cell physiology and disease, Wellcome Centre for Mitochondrial Research, G6239280494, G6868616705, Reversibility and tissue specificity of mitochondrial translation defects in early childhood, Exosomal protein deficiencies: how abnormal RNA metabolism results in childhood-onset neurological diseases, G8597009950, G8758915577, Wellcome Centre for Mitochondrial Research
OpenAlex ID: W3008617433
